Risk of Uncertain Market Advantage for Products Under Development
First written in FY2016. 11 of 22 entries say "Worsened", first in FY2017-Q1. Latest entry: 2026-11-10.
Nippi moved to the "Worse" side of this theme in 2018.
1 other company's latest entry also says "Worsened".
- FY2026-H1RestatedAnnual report
「Gelatin sales increased for prepared-food applications but struggled and declined for gummy and capsule applications. Domestic peptide sales for pharmaceutical and health-food applications remained firm, but overseas sales were adversely affected by intensified price competition, resulting in an overall decline in revenue.」
Overseas sales, including peptides, continue to struggle amid intensified price competition, and the challenge of securing a competitive advantage in the market for high-value-added products remains. - FY2025WorsenedAnnual report
「Domestic peptide sales declined because of intensified price competition and the impact of a health-damage issue involving health-food supplements that occurred in March last year. Overseas sales also declined because of the advance of low-priced Chinese products and the treated-water issue.」
Intensified price competition in domestic and overseas peptide sales, compounded by the advance of low-priced Chinese products, resulted in lower sales and revenue. - FY2025-H1WorsenedAnnual report
「Peptide sales declined as both domestic and export sales struggled because of intensifying price competition, a health-damage incident involving health foods, and the impact of treated water.」
Intensified price competition in domestic and overseas peptide sales resulted in lower revenue, demonstrating that even research and development products and high-value-added products cannot easily secure a competitive advantage in the market. - FY2024-Q3MaterialisedAnnual report
「Although export sales to Southeast Asia remained strong, sales to North America struggled because of customers’ inventory adjustments and intensified competition, resulting in an overall decline in revenue.」
Difficulties in exports to North America due to inventory adjustments and intensified competition resulted in lower revenue, showing that risks relating to market competitiveness and the competitive environment continue to materialize. - FY2021RestatedAnnual report
「The products manufactured and sold by the Group, including collagen casings, gelatin, peptides, collagen cosmetics, linkers and medical equipment related to iPS cells, rely heavily on development centered at the Group’s research laboratories. The Group will continue to focus on development in each business as before, but even high-quality products under development may not necessarily achieve an advantage over competitors amid an economic environment of intensifying competition from low-priced products and new market entrants.」
The possibility that the quality of research and development products alone cannot secure an advantage amid competition from low-priced products and new market entrants continues. - FY2020RestatedAnnual report
「Even if products under development are of high quality, they may not necessarily achieve an advantage over competitors amid an economic environment of intensifying competition from low-priced products and new market entrants.」
The possibility that research and development products cannot secure an advantage over competitors despite superior quality, due to competition from low-priced products and new market entrants, continues. - FY2020-Q1RestatedAnnual report
「The company is working diligently to improve profitability in export sales amid severe price competition.」
Severe price competition in overseas markets continues, and efforts to improve profitability are ongoing. - FY2019WorsenedAnnual report
「As a result, revenue from the collagen casings business was ¥9,242 million, up 5.6% year on year. The operating loss was ¥108 million, compared with operating profit of ¥775 million in the previous consolidated fiscal year, and the segment loss was ¥800 million, compared with segment profit of ¥123 million in the previous consolidated fiscal year.」
Although export sales volumes increased, intense price competition with competitors and depreciation expenses for the new plant and other factors resulted in an annual segment loss of ¥800 million. - FY2019-Q3WorsenedAnnual report
「Although export sales increased through measures to expand sales intended to reduce inventories, the business faced severe price competition.」
Although export sales increased through measures to expand sales, severe price competition continued. The collagen casings business recorded a segment loss, and profitability issues caused by market competition continued and worsened. - FY2019-Q2WorsenedAnnual report
「Although export sales volume increased substantially as a result of sales expansion initiatives aimed at reducing inventories, the company is facing severe price competition.」
Although export sales volumes increased, severe price competition overseas continued, and the collagen casings business recorded an operating loss and a segment loss. - FY2019-Q1WorsenedAnnual report
「Although export sales increased as a result of measures to expand sales, profitability declined substantially due to intense price competition and the depreciation burden of the new plant. As a result, net sales were ¥2,578 million, up 15.1% year on year, operating profit was ¥3 million, down 98.8%, and the segment reported a loss of ¥165 million, compared with segment profit of ¥144 million in the same quarter of the previous year.」
Severe price competition in overseas markets coincided with depreciation expenses for the new plant. Although revenue increased, operating profit fell 98.8% and the segment recorded a loss. - FY2018WorsenedAnnual report
「As a result, revenue from the collagen casings business was ¥8,752 million, up 2.5% year on year. Operating profit was ¥775 million, down 45.1%, partly because of intensified price competition in overseas markets, and segment profit was ¥123 million, down 83.8%.」
Intensified price competition in overseas markets resulted in substantial declines in operating profit and segment profit, while difficulties in domestic sales due to the shift back to natural sheep casings continued. - FY2018-Q2RestatedAnnual report
「Domestic sales remained sluggish as the trend toward returning to natural sheep casings continued. Although the results of measures to expand overseas sales have begun to emerge, efforts to expand sales overseas are still under way.」
While there are signs of progress in overseas expansion, domestic sales continue to struggle because of the shift back to natural sheep casings, and conditions relating to market competitiveness remain mixed. - FY2018-Q1Some progress in overseas expansion, while domestic sales continue to struggleAnnual report
「Measures to expand overseas sales have produced some results, but domestic sales remained sluggish as the trend toward returning to natural sheep casings continued, and difficulties persisted.」
Conditions relating to market competitiveness were mixed: overseas expansion produced some results, while domestic sales continued to struggle because of the shift back to natural sheep casings. - FY2017RestatedAnnual report
「The products manufactured and sold by the Group, including collagen casings, gelatin, peptides, collagen cosmetics, linkers and medical materials related to iPS cells, rely heavily on development centered at the Group’s research laboratories. The Group will continue to focus on development in each business as before, but even high-quality products under development may not necessarily achieve a market advantage amid an economic environment of intensifying competition from low-priced products and new market entrants.」
The possibility that the quality of research and development products alone cannot secure a market advantage, including amid competition from low-priced products and new market entrants, was reiterated. - FY2017-Q3RestatedAnnual report
「Although manufacturing costs have declined, domestic sales remained sluggish as the trend toward returning to natural sheep casings continued, while export sales continued to struggle amid intensifying price competition.」
Weak domestic sales due to the continued shift back to natural sheep casings and intensified price competition and difficulties in export sales continued. - FY2017-Q2RestatedAnnual report
「Domestic sales remained sluggish as the trend toward returning to natural sheep casings continued, while export sales continued to struggle amid intensifying price competition.」
Weak domestic sales due to the continued shift back to natural sheep casings and intensified price competition and difficulties in export sales continued. - FY2017-Q1WorsenedAnnual report
「Although raw-material and fuel prices have declined, domestic sales remained sluggish as the trend toward returning to natural sheep casings continued, while export sales struggled amid intensifying price competition.」
The actual business results reflected intensified price competition and difficulties in export sales, including competition from low-priced products and new market entrants. - FY2016First statedAnnual report
「Even if products under development are of high quality, they may not necessarily achieve a competitive advantage in the market amid an economic environment of intensifying competition from low-priced products and new market entrants.」
For products dependent on research and development, high quality alone may not secure a market advantage amid competition from low-priced products and new market entrants.